Search results
Results From The WOW.Com Content Network
Last Friday, the Medicines and Healthcare Products Regulatory Agency approved Merck & Co Inc’s (NYSE:MRK) Winrevair (sotatercept) for adult patients with pulmonary arterial hypertension (PAH).
Medac – Medac (UK), Scion House, University of Stirling; MediSense – MediSense, Abbott Laboratories Ltd; Menarini – A. Menarini Pharma UK SRL; Menarini Diagnostics – A. Menarini Diagnostics; Merck – Merck Pharmaceuticals; Merck Consumer Health – Seven Seas Ltd; Merck & Co. – Merck Sharp & Dohme Ltd; Milupa – Milupa Ltd; MSD ...
FRANKFURT (Reuters) -Merck KGaA's experimental multiple sclerosis (MS) drug missed the primary goal in highly anticipated late-stage trials, dealing a major blow to the German company's growth ...
Coat of arms of the Darmstadt branch of the Merck family Coat of arms of the Hamburg branch of the Merck family Engel-Apotheke. The Merck family is a German noble family of industrialists and bankers, known for establishing the world's oldest pharmaceutical company Merck, its American former subsidiary Merck & Co. (MSD), which is now an independent company, as well as the Hamburg merchant bank ...
The Merck family still controls a majority of 70.3% of the company's shares. The Merck Group includes around 250 companies in 180 countries; the current main parent company of the group, since 1995, is named Merck KGaA, and is itself mainly owned by the former main parent company, E. Merck oHG, which now operates as a holding company.
Merck & Co Inc (NYSE: MRK) and Ridgeback Biotherapeutics announced data from two real-world evidence studies evaluating Lagevrio (molnupiravir), an investigational oral antiviral COVID-19 medicine.
Get breaking news and the latest headlines on business, entertainment, politics, world news, tech, sports, videos and much more from AOL
Etoricoxib, sold under the brand name Arcoxia, is a selective COX-2 inhibitor developed and commercialized by Merck.It is approved in 63 countries worldwide as of 2007, except the United States where the Food and Drug Administration sent a Non Approvable Letter to Merck and required them to provide additional data.